We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against other high growth international stocks to invest in now.

What To Expect From The Stock Market in 2025?

On January 15, Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company shared his outlook for 2025. He believes that the market has lost some of its momentum as the prospects of more rate cuts in 2025 have gone slimmer. One of the reasons for less likely rate cuts came a few weeks ago with a stronger-than-expected job market report, which sparked a market dip. Moreover, on the same day, long-term interest rates went higher. The 10-year treasury yield climbed closer to the 5% mark which has haunted stocks in the past.

However, Timmer believes the market is still in a bull phase, primarily driven by rising earnings, which he expects will continue to support market growth. This optimism is grounded in the historical performance of bull markets, where earnings often play a crucial role in sustaining upward momentum. He pointed out that as bull markets mature, they typically experience greater volatility. This means that even minor disruptions can lead to significant market fluctuations. High price-to-earnings (P/E) ratios contribute to this sensitivity, as elevated valuations can make the market more susceptible to corrections. Timmer also highlighted his concerns over interest rates, specifically, the Fed’s ability to cut rates, which are likely to persist. This “interest-rate angst” could continue influencing market behavior throughout the year, as investors will continue to grapple with how rate changes can affect stock valuations and overall economic conditions.

Moreover, Timmer also discussed the shifting dynamics in the stock market, particularly focusing on the transition from a narrow leadership group to a broader market participation. He noted that in the latter half of 2024, there was a notable shift in market leadership from the “Magnificent 7”, to a wider array of stocks. This broadening indicates that more sectors and companies are contributing to market gains, which is generally seen as a positive sign for overall market health. However, since mid-December, following the Fed’s reduced expectations for interest rate cuts, the market has lost momentum, as only 24% of stocks were trading above their 50-day moving average, and just 29% of S&P 500 stocks were outperforming the index. This indicates a narrowing participation in market gains, which is concerning for investors who prefer broad-based growth.

While talking about large-cap stock performance, Timmer raises the question of whether this trend of narrow leadership will persist. He suggested that trends continue to move in the same direction until a significant change occurs. Given that large-cap growth stocks have dominated for years, it is reasonable to assume that they may continue to lead. However, he also cautioned the investors that as per the concept of mean reversion, asset prices will eventually return to their historical averages and when this happens, it could lead to sharp corrections in stock prices. Timmer believes that while 2024 was a “Goldilocks year,” for earnings and valuations, this year can be a tussle between higher earnings and rising long-term interest rates, thereby resulting in a volatile market.

Our Methodology

To curate the list of 12 high-growth international stocks to invest in now, we used the Finviz stock screener and Seeking Alpha. We used the screener as a starting point of our research to get (Ex-USA) stocks that have grown their revenue by more than 15% during the last 5 years. Next, we checked these stocks for 10-year revenue growth rates from Seeking Alpha and selected only those stocks that had grown by more than 25% during the last decade. Lastly, we ranked the stocks in ascending order of the number of hedge fund holders sourced from Insider Monkey’s third-quarter database.

Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

argenx SE (NASDAQ:ARGX)

10-Year Revenue Growth Rate: 79.79%

Number of Hedge Fund Holders: 43

Founded in 2008, argenx SE (NASDAQ:ARGX) is a Netherlands-based biopharmaceutical company focused on developing antibody-based therapies for autoimmune diseases and cancer. The company is known for its Vyvgart flagship drug, recognized as the first approved neonatal Fc receptor (FcRn) blocker in the United States, European Union, Japan, and other regions for treating generalized myasthenia gravis (gMG).

Vyvgart got approved in 2021 and has since then significantly exceeded expectations. Analysts expect that it could generate over $5 billion in peak sales, driven by a substantial unmet need in this therapeutic area. During the fiscal third quarter of 2024, argenx SE (NASDAQ:ARGX) grew its revenue by 74% year-over-year to reach $589 million. Out of this total revenue, Vyvart contributed $573 million from net global sales.

Argenx SE (NASDAQ:ARGX) is advancing several other candidates through its antibody discovery platform, including empasiprubart, which targets rare neurological diseases like multifocal motor neuropathy (MMN). Moreover, management has signed a partnership with Zai Lab to market Vyvgart in China, which adds potential for long-term sales growth. It is one of the high-growth international stocks to invest in now.

Overall, ARGX ranks 6th on our list of high growth international stocks to invest in now. While we acknowledge the potential of ARGX to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARGX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

Disclosure: None. This article is originally published at Insider Monkey.